ClinicalTrials.gg
CompletedNCT00046475Updated Jun 11, 2021Results posted

A Study for Patients With Neurogenic Orthostatic Hypotension

A Phase 4 interventional study of Midodrine Hydrochloride in Hypotension, Orthostatic, sponsored by Shire. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled Dec 1997, registered Sep 2002).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing midodrine in Hypotension, Orthostatic — none open to participants now, none under way, none of them phase 3. Midodrine · Hypotension, Orthostatic.

Enrollment
4th of 16
140 · median 42
Started
1997
the only one that year
Phase 4
6 of 16
none open now
Registered
3rd of 16
by date
Lead sponsor
5 of 16
Shire

Among the 16 studies testing midodrine in Hypotension, Orthostatic, this one is the 4th largest by enrollment, is the only one that started in 1997, is one of 6 in phase 4, and was the 3rd registered.

Hypotension, Orthostatic

159 studies on the registry are indexed under Hypotension, Orthostatic; 35 are open to participants now.

Browse Hypotension, Orthostatic studies →

Open to participants now

None of the 16 studies testing midodrine in Hypotension, Orthostatic is open now. The open studies under Hypotension, Orthostatic, anywhere →

About midodrine

Midodrine: first FDA approval 1996 (PROAMATINE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 23 Hypotension, Orthostatic studies recruiting now, 8 (35%) set no upper age limit and 8 (35%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing midodrine in Hypotension, Orthostatic as a file.
02

Study summary

We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright position) due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathies (i.e. neurogenic orthostatic hypotension). Symptoms of low blood pressure include dizziness, lightheadedness, changes in vision and generalized weakness upon standing. The main effect of the drug being studied is to increase blood pressure in the upright position so symptoms will decrease.

The purpose of this clinical study is to further assess the clinical benefit of midodrine hydrochloride (ProAmatine®), an approved treatment for orthostatic hypotension. During the course of the study, participants will receive either ProAmatine® or a placebo. Assessments will be made using questionnaires that measure symptom and activity levels. Blood pressure in the lying down and standing positions will be measured at each visit.

03

Conditions studied

  • Hypotension, Orthostatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The male or female patient must be 18 years of age or older and ambulatory.
  • Female patients must be: without menses for at least 12 months prior to screening; surgically sterilized (bilateral tubal ligation or hysterectomy); or practicing adequate means of . Adequate means of birth control is defined as the use of prescribed birth control pills, IUD, or hormonal injections from at least one month prior to screening. Double-barrier methods and abstinence are also acceptable forms of birth control.
  • The patient has been diagnosed with symptomatic orthostatic hypotension due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathies (i.e. neurogenic orthostatic hypotension).
  • The patient manifests at least one of the following symptoms while standing or has a history of one of the following when not treated for orthostatic hypotension: dizziness, lightheadedness, feeling faint or feeling like they may black out.
  • The patient is willing and able to undergo the procedures required by this protocol including morning office visits, assessment completion, protocol compliance and participation in the .
  • The patient signs an Institutional-Review-Board approved written form prior to any study procedures taking place.

Exclusion criteria

Exclusion Criteria:

  • The patient is pregnant or lactating female.
  • The patient has pre-existing sustained supine hypertension greater than 180 systolic and 110 diastolic mmHg.
  • The patient is taking medications such as vasodilators, pressors, diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, combined alpha and beta-blockers, MAOI's, herbals, or specific mixed effect medications.
  • The Principal Investigator deems any laboratory test abnormality .
  • The patient has a diagnosis of any of the following disorders at the time of screening: pheochromocytoma; cardiac conditions including: congestive heart failure within the previous 6 months, myocardial infarction within the previous 6 months, symptomatic coronary artery disease, history of ventricular tachycardia, or uncontrolled cardiac arrhythmias; thyrotoxicosis; uncontrolled diabetes mellitus (uncontrolled defined as HgbA1c greater than or equal to 10%); history of cerebrovascular accident, (TIA) or symptomatic carotid artery stenosis within the previous 6 months; history of coagulopathies; pulmonary hypertension; severe psychiatric disorders; renal failure (creatinine equal to or greater than 2 times the ).
  • The patient has a concurrent chronic or acute illness, disability, or other condition that might confound the results of the tests and/or measurements administered in this trial, or that might increase the risk to the patient.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
140 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale

    Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. Higher scores indicate more severe disease.

    Time frame: End of 2-week treatment period

  2. Re-analysis of The Post-treatment Score For Item 1 of The OHSA Scale, Excluding Two Sites

    Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. Higher scores indicate more severe disease.

    Time frame: End of 2-week treatment period

  3. Post-treatment OHSA Item 1 Score of United States (US) Participants With Mild/Moderate Disease According to The Clinical Global Impressions-Severity (CGI-S) Scale

    Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. The results are reported by degree of severity according to the CGI-S scale, which uses 4 categories to describe disease severity: Mild, Moderate, Marked, and Severe. The Item 1 scores reported are grouped for participants with Mild or Moderate disease severity. Higher scores indicate more severe disease.

    Time frame: End of 2-week treatment period

  4. Post-treatment OHSA Item 1 Score of US Participants With Marked/Severe Disease According to The CGI-S Scale

    Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. The results are reported by degree of severity according to the CGI-S scale, which uses 4 categories to describe disease severity: Mild, Moderate, Marked, and Severe. The Item 1 scores reported are grouped for participants with Marked or Severe disease severity. Higher scores indicate more severe disease.

    Time frame: End of 2-week treatment period

Secondary outcomes

  1. Change From Baseline in The OHSA Items 2 Through 6 Scores

    Items 2 through 6 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of the following symptoms whenever he or she was standing and that improved when he or she sat down or laid down: Item 2 addresses problems with vision (blurring, seeing spots, tunnel vision, etc); Item 3, weakness; Item 4, fatigue; Item 5, trouble concentrating; and Item 6, head or neck discomfort. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.

    Time frame: From the time of titration until the end of treatment

  2. Change From Baseline in The OHSA Composite Symptom Score

    The OHSA composite symptom score was calculated by taking the average of the ratings for the symptoms present at Baseline. Participants were asked to rate symptoms by using a 0-10 scale (0 meaning not bothered and 10 meaning the worst). For subsequent visits, only those symptoms present at Baseline were scored. In this manner, a score was produced that represents the severity (and subsequent change in severity) of the patient's neurogenic OH symptoms, regardless of how many symptoms are presented at Baseline. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.

    Time frame: From the time of titration until the end of treatment

  3. Change From Baseline in The Orthostatic Hypotension Daily Activity Scale (OHDAS) Items 1 Through 4 Scores

    The OHDAS had 4 items that asked the patient to give a graduated score from 0 (no limitation due to OH) to 10 (complete limitation due to OH). Item 1 addressed activities that required standing for a short time; Item 2, activities that required standing for a long time; Item 3, activities that required walking for a short time; and Item 4, activities that required walking for a long time. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.

    Time frame: From the time of titration until the end of treatment

  4. Change From Baseline in The Orthostatic Hypotension Global Daily Activity Score

    The OHDAS global daily activity score was calculated as the average of all daily activity item scores. The OHDAS had 4 items that asked the patient to give a graduated score from 0 (no limitation due to OH) to 10 (complete limitation due to OH) to activities that required standing for a short time, standing for a long time, walking for a short time, walking for a long time. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.

    Time frame: From the time of titration until the end of treatment

  5. Percent of Participants Scored as Improved on The Clinician Version of The Clinical Global Impressions Improvement (CGI-I) Scale

    The CGI-I is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Clinical Global Impressions ratings are completed with respect to neurogenic OH symptoms. A value of 0 was used if the investigator or patient assessment was not performed. The improved category is made up of patients who were evaluated as very much improved, much improved, or slightly improved for the classification of "Overall Improvement." The CGI-I was completed at Visit 5 (Period 2) and Visit 6 (study completion).

    Time frame: From the time of titration until the end of treatment

  6. Percent of Participants Scored as Improved on The Patient Version of The CGI-I Scale

    The CGI-I is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Clinical Global Impressions ratings are completed with respect to neurogenic OH symptoms. A value of 0 was used if the investigator or patient assessment was not performed. The improved category is made up of patients who were evaluated as very much improved, much improved, or slightly improved for the classification of "Overall Improvement." The CGI-I was completed at Visit 5 (Period 2) and Visit 6 (study completion).

    Time frame: From the time of titration until the end of treatment

  7. Change From Baseline in Standing Blood Pressure (BP)

    Standing BP was measured at Visit 5 (Period 2) and Visit 6 (study completion) and compared to measurements taken at Visit 3A (titration). Standing BP was measured 3 minutes after the patient rose from the supine position or as soon as the patient indicated they needed to sit down. If the patient indicated he or she needed to sit down, the BP measurement was taken while in the standing position, before the patient sat down.

    Time frame: From the time of titration until the end of treatment

  8. Change From Baseline in Supine BP

    Supine BP was measured at Visit 5 (Period 2) and Visit 6 (study completion) and compared to measurements taken at Visit 3A (titration). Supine BP was measured after the patient had been in the supine position for 5 minutes.

    Time frame: From the time of titration until the end of treatment

  9. Change From Baseline in Short Form-36 (SF-36) Version 2 Health Survey Questionnaire Scores

    The SF-36 consists of 36 items in eight domains: physical functioning, general health, role-physical, bodily pain, vitality, social functioning, role-emotional, and mental health. Version 2 references "one week ago" for some questions. Raw scale scores for the SF-36 were transformed to a 0-100 scale with a higher score indicating a better quality of life. A positive change from baseline indicates that symptoms have improved. The SF-36 was completed at Visit 5 (Period 2) and Visit 6 (study completion) and compared to the score from Visit 3A (titration).

    Time frame: From the time of titration until the end of treatment

  10. Test Reliability of the Intent-to-Treat (ITT) Population

    Item 1 of the OHSA, the OHSA composite score, and the OHDAS global daily activity score were analyzed for test-retest reliability as a measure of validity. Test-retest reliability is the Pearson product-moment correlation coefficient calculated between OHQ scores at Visit 3A (baseline measure) and OHQ scores at Visit 5 for the subjects who received Placebo during Randomization Period 1.

    Time frame: From the time of titration until the end of treatment

  11. Responsiveness of the Intent-to-Treat (ITT) Population

    Item 1 of the OHSA, the OHSA composite score, and the OHDAS global daily activity score were analyzed for responsiveness as a measure of validity. Assuming that subjects who received Placebo during Randomization Period 1 are stable between Visit 3A and Visit 5, and using them as the stable subjects, responsiveness was calculated as \[(OH CFB in Midodrine group)-(OH CFB in Placebo group)\]/(SD of OH CFB in Placebo group), where CFB is change from baseline, SD is the standard deviation of OH CFB of the stable subjects; the value reported is the quotient of this equation.

    Time frame: From the time of titration until the end of treatment

  12. Convergent Validity of the Intent-to-Treat (ITT) Population

    Item 1 of the OHSA and the OHSA composite score were analyzed for convergent validity with the CGI-I-Clinician scores. The change from baseline in the CGI-I scores are correlated with the OHSA Item 1 score change from baseline and the OHSA composite score change from baseline for the subjects in the ITT population. Values shown are Spearman correlation coefficients.

    Time frame: From the time of titration until the end of treatment

07

Results

Posted May 12, 2015

Participant flow

Screening/Washout Period (Up to 2 Weeks)
Participant flow — Screening/Washout Period (Up to 2 Weeks)
MilestoneAll Enrolled ParticipantsMidodrine/PlaceboPlacebo/Midodrine
Started14000
Completed13600
Not completed400
Titration (1 Week)
Participant flow — Titration (1 Week)
MilestoneAll Enrolled ParticipantsMidodrine/PlaceboPlacebo/Midodrine
Started13600
Completed13600
Not completed000
Treatment Period 1 (Up to 2 Weeks)
Participant flow — Treatment Period 1 (Up to 2 Weeks)
MilestoneAll Enrolled ParticipantsMidodrine/PlaceboPlacebo/Midodrine
Started04560
Completed04559
Not completed001
Treatment Period 2 (Up to 2 Weeks)
Participant flow — Treatment Period 2 (Up to 2 Weeks)
MilestoneAll Enrolled ParticipantsMidodrine/PlaceboPlacebo/Midodrine
Started04559
Completed04459
Not completed010

Outcome measures

PrimaryPost-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale

Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. Higher scores indicate more severe disease.

Time frame:
End of 2-week treatment period
Reported as:
Mean · scores on a scale
Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale
scores on a scaleMidodrine HClPlacebo
Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale4.1 ± 2.95.2 ± 2.7
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = <0.001 (The P-value is based on an ANOVA model with post-treatment responses for OHSA Item 1 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
PrimaryRe-analysis of The Post-treatment Score For Item 1 of The OHSA Scale, Excluding Two Sites

Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. Higher scores indicate more severe disease.

Time frame:
End of 2-week treatment period
Reported as:
Mean · scores on a scale
Re-analysis of The Post-treatment Score For Item 1 of The OHSA Scale, Excluding Two Sites
scores on a scaleMidodrine HClPlacebo
Re-analysis of The Post-treatment Score For Item 1 of The OHSA Scale, Excluding Two Sites4.3 ± 2.935.1 ± 2.76
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.011 (The P-value is based on an ANOVA model with post-treatment responses for OHSA Item as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
SecondaryChange From Baseline in The OHSA Items 2 Through 6 Scores

Items 2 through 6 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of the following symptoms whenever he or she was standing and that improved when he or she sat down or laid down: Item 2 addresses problems with vision (blurring, seeing spots, tunnel vision, etc); Item 3, weakness; Item 4, fatigue; Item 5, trouble concentrating; and Item 6, head or neck discomfort. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.

Time frame:
From the time of titration until the end of treatment
Reported as:
Mean · scores on a scale
Change From Baseline in The OHSA Items 2 Through 6 Scores
scores on a scaleMidodrine HClPlacebo
Item 2, n= 103, 103-1.2 ± 2.5-0.2 ± 2.3
Item 3, n=103, 103-1.3 ± 3.2-0.4 ± 2.5
Item 4, n=103, 103-1.2 ± 3.2-0.4 ± 2.6
Item 5, n=102, 102-0.4 ± 2.70.0 ± 2.2
Item 6, n=102, 102-0.8 ± 2.6-0.5 ± 2.1
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = <0.001 (The P-value is based on an ANOVA model with post-treatment responses for OHSA Item 2 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.002 (The P-value is based on an ANOVA model with post-treatment responses for OHSA Item 3 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.004 (The P-value is based on an ANOVA model with post-treatment responses for OHSA Item 4 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.026 (The P-value is based on an ANOVA model with post-treatment responses for OHSA Item 5 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.226 (The P-value is based on an ANOVA model with post-treatment responses for OHSA Item 6 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
SecondaryChange From Baseline in The OHSA Composite Symptom Score

The OHSA composite symptom score was calculated by taking the average of the ratings for the symptoms present at Baseline. Participants were asked to rate symptoms by using a 0-10 scale (0 meaning not bothered and 10 meaning the worst). For subsequent visits, only those symptoms present at Baseline were scored. In this manner, a score was produced that represents the severity (and subsequent change in severity) of the patient's neurogenic OH symptoms, regardless of how many symptoms are presented at Baseline. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.

Time frame:
From the time of titration until the end of treatment
Reported as:
Mean · scores on a scale
Change From Baseline in The OHSA Composite Symptom Score
scores on a scaleMidodrine HClPlacebo
Change From Baseline in The OHSA Composite Symptom Score-1.3 ± 2.5-0.54 ± 1.952
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.002 (The P-value is based on an ANOVA model with post-treatment composite symptom score as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
SecondaryChange From Baseline in The Orthostatic Hypotension Daily Activity Scale (OHDAS) Items 1 Through 4 Scores

The OHDAS had 4 items that asked the patient to give a graduated score from 0 (no limitation due to OH) to 10 (complete limitation due to OH). Item 1 addressed activities that required standing for a short time; Item 2, activities that required standing for a long time; Item 3, activities that required walking for a short time; and Item 4, activities that required walking for a long time. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.

Time frame:
From the time of titration until the end of treatment
Reported as:
Mean · scores on a scale
Change From Baseline in The Orthostatic Hypotension Daily Activity Scale (OHDAS) Items 1 Through 4 Scores
scores on a scaleMidodrine HClPlacebo
Item 1, n=102, 101-1.1 ± 2.90-0.4 ± 1.95
Item 2, n=98, 99-1.8 ± 3.14-0.6 ± 2.41
Item 3, n=100, 101-1.1 ± 2.71-0.2 ± 2.16
Item 4, n=89, 90-1.3 ± 3.31-0.5 ± 2.57
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = <0.001 (The P-value is based on an ANOVA model with post-treatment responses for OHDAS Item 1 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = <0.001 (The P-value is based on an ANOVA model with post-treatment responses for OHDAS Item 2 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = <0.001 (P-value is based on an ANOVA model with post-treatment responses for OHDAS Item 3 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.001 (The P-value is based on an ANOVA model with post-treatment responses for OHDAS Item 4 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
SecondaryChange From Baseline in The Orthostatic Hypotension Global Daily Activity Score

The OHDAS global daily activity score was calculated as the average of all daily activity item scores. The OHDAS had 4 items that asked the patient to give a graduated score from 0 (no limitation due to OH) to 10 (complete limitation due to OH) to activities that required standing for a short time, standing for a long time, walking for a short time, walking for a long time. Symptomatology was assessed at Visit 3A (titration), Visit 5 (Period 2), and Visit 6 (study completion). A negative change from baseline indicates that symptoms have improved.

Time frame:
From the time of titration until the end of treatment
Reported as:
Mean · scores on a scale
Change From Baseline in The Orthostatic Hypotension Global Daily Activity Score
scores on a scaleMidodrine HClPlacebo
Change From Baseline in The Orthostatic Hypotension Global Daily Activity Score-1.4 ± 2.6-0.4 ± 1.9
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = <0.001 (The P-value is based on an ANOVA model with post-treatment global daily activity score as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
SecondaryPercent of Participants Scored as Improved on The Clinician Version of The Clinical Global Impressions Improvement (CGI-I) Scale

The CGI-I is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Clinical Global Impressions ratings are completed with respect to neurogenic OH symptoms. A value of 0 was used if the investigator or patient assessment was not performed. The improved category is made up of patients who were evaluated as very much improved, much improved, or slightly improved for the classification of "Overall Improvement." The CGI-I was completed at Visit 5 (Period 2) and Visit 6 (study completion).

Time frame:
From the time of titration until the end of treatment
Reported as:
Number · percent of participants
Percent of Participants Scored as Improved on The Clinician Version of The Clinical Global Impressions Improvement (CGI-I) Scale
percent of participantsMidodrine HClPlacebo
Percent of Participants Scored as Improved on The Clinician Version of The Clinical Global Impressions Improvement (CGI-I) Scale73.145.2
SecondaryPercent of Participants Scored as Improved on The Patient Version of The CGI-I Scale

The CGI-I is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Clinical Global Impressions ratings are completed with respect to neurogenic OH symptoms. A value of 0 was used if the investigator or patient assessment was not performed. The improved category is made up of patients who were evaluated as very much improved, much improved, or slightly improved for the classification of "Overall Improvement." The CGI-I was completed at Visit 5 (Period 2) and Visit 6 (study completion).

Time frame:
From the time of titration until the end of treatment
Reported as:
Number · percent of participants
Percent of Participants Scored as Improved on The Patient Version of The CGI-I Scale
percent of participantsMidodrine HClPlacebo
Percent of Participants Scored as Improved on The Patient Version of The CGI-I Scale62.550.0
SecondaryChange From Baseline in Standing Blood Pressure (BP)

Standing BP was measured at Visit 5 (Period 2) and Visit 6 (study completion) and compared to measurements taken at Visit 3A (titration). Standing BP was measured 3 minutes after the patient rose from the supine position or as soon as the patient indicated they needed to sit down. If the patient indicated he or she needed to sit down, the BP measurement was taken while in the standing position, before the patient sat down.

Time frame:
From the time of titration until the end of treatment
Reported as:
Mean · mmHg
Change From Baseline in Standing Blood Pressure (BP)
mmHgMidodrine HClPlacebo
Systolic Pressure10.7 ± 21.682.8 ± 19.55
Diastolic Pressure5.9 ± 14.461.5 ± 13.03
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.002 (The P-value is based on an ANOVA model with change from baseline standing systolic blood pressure as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.010 (The P-value is based on an ANOVA model with change from baseline standing diastolic blood pressure as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
SecondaryChange From Baseline in Supine BP

Supine BP was measured at Visit 5 (Period 2) and Visit 6 (study completion) and compared to measurements taken at Visit 3A (titration). Supine BP was measured after the patient had been in the supine position for 5 minutes.

Time frame:
From the time of titration until the end of treatment
Reported as:
Mean · mmHg
Change From Baseline in Supine BP
mmHgMidodrine HClPlacebo
Systolic Pressure7.6 ± 22.76-0.9 ± 15.74
Diastolic Pressure3.4 ± 11.890.3 ± 10.35
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = <0.001 (The P-value is based on an ANOVA model with change from baseline supine systolic blood pressure as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.002 (The P-value is based on an ANOVA model with change from baseline supine diastolic blood pressure as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
SecondaryChange From Baseline in Short Form-36 (SF-36) Version 2 Health Survey Questionnaire Scores

The SF-36 consists of 36 items in eight domains: physical functioning, general health, role-physical, bodily pain, vitality, social functioning, role-emotional, and mental health. Version 2 references "one week ago" for some questions. Raw scale scores for the SF-36 were transformed to a 0-100 scale with a higher score indicating a better quality of life. A positive change from baseline indicates that symptoms have improved. The SF-36 was completed at Visit 5 (Period 2) and Visit 6 (study completion) and compared to the score from Visit 3A (titration).

Time frame:
From the time of titration until the end of treatment
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form-36 (SF-36) Version 2 Health Survey Questionnaire Scores
scores on a scaleMidodrine HClPlacebo
General Health1.97 ± 7.8011.59 ± 6.027
Physical Functioning1.99 ± 8.2551.71 ± 8.034
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.569 (The P-value is based on an ANOVA model with SF-36 general health score as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
  • Midodrine HCl vs Placebo · ANOVA · p = 0.578 (The P-value is based on an ANOVA model with SF-36 physical functioning score as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and patient within sequence as random effect.)
SecondaryTest Reliability of the Intent-to-Treat (ITT) Population

Item 1 of the OHSA, the OHSA composite score, and the OHDAS global daily activity score were analyzed for test-retest reliability as a measure of validity. Test-retest reliability is the Pearson product-moment correlation coefficient calculated between OHQ scores at Visit 3A (baseline measure) and OHQ scores at Visit 5 for the subjects who received Placebo during Randomization Period 1.

Time frame:
From the time of titration until the end of treatment
Reported as:
Number · correlation coefficient
Test Reliability of the Intent-to-Treat (ITT) Population
correlation coefficientITT Population
OHSA Item 10.53
OHSA Composite Score0.61
OHDAS Global Daily Activity Score0.66
SecondaryResponsiveness of the Intent-to-Treat (ITT) Population

Item 1 of the OHSA, the OHSA composite score, and the OHDAS global daily activity score were analyzed for responsiveness as a measure of validity. Assuming that subjects who received Placebo during Randomization Period 1 are stable between Visit 3A and Visit 5, and using them as the stable subjects, responsiveness was calculated as \[(OH CFB in Midodrine group)-(OH CFB in Placebo group)\]/(SD of OH CFB in Placebo group), where CFB is change from baseline, SD is the standard deviation of OH CFB of the stable subjects; the value reported is the quotient of this equation.

Time frame:
From the time of titration until the end of treatment
Reported as:
Number · quotient
Responsiveness of the Intent-to-Treat (ITT) Population
quotientITT Population
OHSA Item 1-0.4099
OHSA Composite Score-0.4014
OHDAS Global Daily Activity Score-0.4903
SecondaryConvergent Validity of the Intent-to-Treat (ITT) Population

Item 1 of the OHSA and the OHSA composite score were analyzed for convergent validity with the CGI-I-Clinician scores. The change from baseline in the CGI-I scores are correlated with the OHSA Item 1 score change from baseline and the OHSA composite score change from baseline for the subjects in the ITT population. Values shown are Spearman correlation coefficients.

Time frame:
From the time of titration until the end of treatment
Reported as:
Number · correlation coefficient
Convergent Validity of the Intent-to-Treat (ITT) Population
correlation coefficientITT Population
OHSA Item 1, n=1030.36
OHSA Composite Score, n=1020.38
PrimaryPost-treatment OHSA Item 1 Score of United States (US) Participants With Mild/Moderate Disease According to The Clinical Global Impressions-Severity (CGI-S) Scale

Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. The results are reported by degree of severity according to the CGI-S scale, which uses 4 categories to describe disease severity: Mild, Moderate, Marked, and Severe. The Item 1 scores reported are grouped for participants with Mild or Moderate disease severity. Higher scores indicate more severe disease.

Time frame:
End of 2-week treatment period
Reported as:
Mean · scores on a scale
Post-treatment OHSA Item 1 Score of United States (US) Participants With Mild/Moderate Disease According to The Clinical Global Impressions-Severity (CGI-S) Scale
scores on a scaleMidodrine HClPlacebo
Post-treatment OHSA Item 1 Score of United States (US) Participants With Mild/Moderate Disease According to The Clinical Global Impressions-Severity (CGI-S) Scale4.4 ± 2.973.8 ± 2.63
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.370 (The p-value is based on an ANOVA model with post-treatment responses for OHSA Item 1 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and subject-within sequence as random effect.)
PrimaryPost-treatment OHSA Item 1 Score of US Participants With Marked/Severe Disease According to The CGI-S Scale

Item 1 of the OHSA asked the patient to rate, using a 0-10 scale (0 meaning not bothered and 10 meaning the worst), his or her impression of the severity of dizziness, lightheadedness, feeling faint, or feeling like you might black out whenever he or she was standing and that improved when he or she sat or laid down. The results are reported by degree of severity according to the CGI-S scale, which uses 4 categories to describe disease severity: Mild, Moderate, Marked, and Severe. The Item 1 scores reported are grouped for participants with Marked or Severe disease severity. Higher scores indicate more severe disease.

Time frame:
End of 2-week treatment period
Reported as:
Mean · scores on a scale
Post-treatment OHSA Item 1 Score of US Participants With Marked/Severe Disease According to The CGI-S Scale
scores on a scaleMidodrine HClPlacebo
Post-treatment OHSA Item 1 Score of US Participants With Marked/Severe Disease According to The CGI-S Scale4.7 ± 2.906.1 ± 2.60
Statistical analysis
  • Midodrine HCl vs Placebo · ANOVA · p = 0.007 (The p-value is based on an ANOVA model with post-treatment responses for OHSA Item 1 as dependent variable, treatment, sequence, period (Visit 5 or 6), as fixed effects, and subject-within sequence as random effect.)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Screening/Washout—1/140 (0.7%)12/140 (8.6%)
Titration—4/136 (2.9%)42/136 (30.9%)
Midodrine HCl—0/104 (0%)22/104 (21.2%)
Placebo—1/105 (1%)23/105 (21.9%)
Follow-up—5/140 (3.6%)23/140 (16.4%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventScreening/WashoutTitrationMidodrine HClPlaceboFollow-up
Neck painMusculoskeletal and connective tissue disorders0/1400/1360/1041/1050/140
Blindness corticalEye disorders0/1401/1360/1040/1050/140
Therapeutic agent poisoningInjury, poisoning and procedural complications0/1401/1360/1040/1050/140
Convulsions NOSNervous system disorders0/1401/1360/1040/1050/140
Orthostatic hypotensionVascular disorders1/1401/1360/1040/1051/140
Cardiac arrestCardiac disorders0/1400/1360/1040/1051/140
Colitis NOSGastrointestinal disorders0/1400/1360/1040/1051/140
Gastrointestinal haemorrhage NOSGastrointestinal disorders0/1400/1360/1040/1051/140
Injury NOSInjury, poisoning and procedural complications0/1400/1360/1040/1051/140
Parkinson's disease NOSNervous system disorders0/1400/1360/1040/1051/140
Most frequent other events
Most frequent other events
EventScreening/WashoutTitrationMidodrine HClPlaceboFollow-up
Headache NOSNervous system disorders1/14013/1366/1047/1055/140
Pruritus NOSSkin and subcutaneous tissue disorders0/14011/1368/1048/1059/140
ParaesthesiaNervous system disorders0/14010/1365/1045/1053/140
Hypertension NOSVascular disorders4/1409/1363/1042/1052/140
DizzinessNervous system disorders3/1407/1363/1045/1055/140
Urinary tract infection NOSInfections and infestations5/1406/1361/1041/1057/140

Baseline characteristics

The intent-to-treat (ITT) population, defined as all patients who were randomly assigned to treatment in the study and have at least one post-randomization Orthostatic Hypotension Questionnaire (OHQ) measurement.

Age, Continuous
Age, Continuous(years)Midodrine/PlaceboPlacebo/MidodrineTotal
Mean62.0 ± 14.2262.2 ± 14.4362.2 ± 14.27
Sex: Female, Male
Sex: Female, Male(Participants)Midodrine/PlaceboPlacebo/MidodrineTotal
Female232447
Male223557
08

Study locations

15 sites
  • North Alabama Neuroscience Research
    Huntsville, Alabama 35801, United States
  • Dr. Harry Pepe & Associates, Inc.
    Miramar, Florida 33023, United States
  • Suncoast Neuroscience Associates, Inc.
    Saint Petersburg, Florida, United States
  • Economou & Associates, LTD
    Chicago, Illinois 60612, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland, United States
  • Michigan Pain and Neurological Institute
    Ann Arbor, Michigan, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • NY Presbyterian Hospital
    New York, New York 10032, United States
  • Medical College of Ohio
    Toledo, Ohio 43614, United States
  • COR Clinical Research, LLC
    Oklahoma City, Oklahoma 73103, United States
  • Westmoreland Neurology Associates Inc.
    Greensburg, Pennsylvania 15601, United States
  • Neurological Associates of Delaware Valley
    Upland, Pennsylvania 19013, United States
  • Diabetes & Glandular Disease Research Associates, PA
    San Antonio, Texas, United States
  • Monarch Medical Research
    Norfolk, Virginia 23502, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 1997 to primary completion in Nov 1999, 23 months.

Results were first posted in May 2015, 15 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2002
First posted
Oct 2, 2002
StartActual
Dec 1, 1997
Primary completionActual
Nov 24, 1999
CompletionActual
Nov 24, 1999
Results first posted
May 12, 2015
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00046475
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Oct 2, 2002
Start date
Dec 1, 1997
Primary completion
Nov 24, 1999
Completion
Nov 24, 1999
Results posted
May 12, 2015
Last update
Jun 11, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midodrine

Start the discussion